BBOT (BridgeBio Oncology Therapeutics) OCF Margin %: 0.00% (As of Mar. 2026)


BBOT BridgeBio Oncology Therapeutics Inc BBOT
12 GF Score
Price $8.40
View Full Analysis

What is BridgeBio Oncology Therapeutics OCF Margin %?

BridgeBio Oncology Therapeutics BBOT +3.70% 12 OCF Margin % is 0.00% as of Mar. 2026. GuruFocus rates BBOT with a GF Score™ of 12/100. Among 949 Biotechnology companies, BridgeBio Oncology Therapeutics ranks worse than 105373.97% on this metric.

OCF Margin % is calculated as Cash Flow from Operations divided by its Revenue. BridgeBio Oncology Therapeutics's Cash Flow from Operations for the three months ended in Mar. 2026 was $-35.92 Mil. BridgeBio Oncology Therapeutics's Revenue for the three months ended in Mar. 2026 was $0.00 Mil. Therefore, BridgeBio Oncology Therapeutics's OCF Margin % for the quarter that ended in Mar. 2026 was 0.00%.

As of today, BridgeBio Oncology Therapeutics's current OCF Yield % is -19.33%.

The historical rank and industry rank for BridgeBio Oncology Therapeutics's OCF Margin % or its related term are showing as below:


BBOT's OCF Margin % is not ranked *
in the Biotechnology industry.
Industry Median: -64.23
* Ranked among companies with meaningful OCF Margin % only.

BridgeBio Oncology Therapeutics OCF Margin % Related Terms

BridgeBio Oncology Therapeutics OCF Margin % Historical Data

* Premium members only.

The historical data trend for BridgeBio Oncology Therapeutics's OCF Margin % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

BridgeBio Oncology Therapeutics OCF Margin % Chart

BridgeBio Oncology Therapeutics Annual Data
Trend Dec23 Dec24 Dec25
OCF Margin %
0.00 0.00 0.00

BridgeBio Oncology Therapeutics Quarterly Data
Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
OCF Margin % Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00
BBOT
12GF Score
BridgeBio Oncology Therapeutics Inc BBOT
OCF Margin % is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

BridgeBio Oncology Therapeutics OCF Margin % Calculation

OCF Margin % is the ratio of Cash Flow from Operations divided by net sales or Revenue, usually presented in percent.

BridgeBio Oncology Therapeutics's OCF Margin for the fiscal year that ended in Dec. 2025 is calculated as

OCF Margin=Cash Flow from Operations (A: Dec. 2025 )/Revenue (A: Dec. 2025 )
=-113.894/0
= %

BridgeBio Oncology Therapeutics's OCF Margin for the quarter that ended in Mar. 2026 is calculated as

OCF Margin=Cash Flow from Operations (Q: Mar. 2026 )/Revenue (Q: Mar. 2026 )
=-35.917/0
= %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about OCF Margin % →
What does a OCF Margin % of 0.00% mean?
BridgeBio Oncology Therapeutics (BBOT) has a OCF Margin % of 0.00% as of Mar. 2026. OCF Margin is the ratio of Cash Flow from Operations to Total Revenue. View historical data on BridgeBio Oncology Therapeutics and its competitors. According to the industry distribution chart, BridgeBio Oncology Therapeutics ranks #999999 out of 949 companies in the Biotechnology industry.
Is BridgeBio Oncology Therapeutics' OCF Margin % too high?
BridgeBio Oncology Therapeutics' current OCF Margin % is 0.00%. Based on the distribution chart, BridgeBio Oncology Therapeutics ranks #999999 out of 949 companies in the Biotechnology industry, which is in the bottom quartile relative to peers. Overall, BridgeBio Oncology Therapeutics has a GF Score™ of 12/100, reflecting its overall financial health beyond just this single metric.
How does BridgeBio Oncology Therapeutics' OCF Margin % compare to FTH and MNPR?
According to the Biotechnology industry distribution chart, BridgeBio Oncology Therapeutics ranks #999999 out of 949 companies for OCF Margin %. This places BridgeBio Oncology Therapeutics in the lower half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good OCF Margin % for a Biotechnology company?
A good OCF Margin % depends on the Biotechnology industry context. However, OCF Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high OCF Margin % mean?
A high OCF Margin % can signal that a stock is expensive relative to its fundamentals. OCF Margin is the ratio of Cash Flow from Operations to Total Revenue. View historical data on BridgeBio Oncology Therapeutics and its competitors. BridgeBio Oncology Therapeutics's current OCF Margin % is 0.00%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is BridgeBio Oncology Therapeutics stock overvalued right now?
BridgeBio Oncology Therapeutics (BBOT) has a current OCF Margin % of 0.00%. The current OCF Margin % is 0.00%. BridgeBio Oncology Therapeutics' overall GF Score™ is 12/100. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is OCF Margin % calculated?
OCF Margin % is calculated from a company's financial statements. For BridgeBio Oncology Therapeutics (BBOT), the current OCF Margin % is 0.00% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

BridgeBio Oncology Therapeutics Business Description

Address 256 East Grand Avenue, Suite 104, South San Francisco, CA, USA, 94080
BridgeBio Oncology Therapeutics Inc, is a clinical-stage biotechnology company that aims to transform the lives of patients with cancers driven by RAS and PI3Ka, the two frequently mutated oncogenes. The Company operates in one operating and reportable segment within the United States, developing oncology therapies through various related development projects.
12GF Score

Get the complete analysis for BBOT

OCF Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$8.40
Price